This market resolves to Yes if the stem-cell treatment for Parkinson’s disease, approved by Japan for manufacturing and sale, becomes commercially available to the public by December 31, 2026. Availability must be verifiable through a reputable announcement by Sumitomo Pharma or a reliable news source.